TETANUS TOXOID ALUM PRECIPITATED “KUO KWANG“

TETANUS TOXOID ALUM PRECIPITATED “KUO KWANG“
Product Description

Tetanus Toxoid Alum Precipitated “KUO KWANG” is a sterile injectable vaccine indicated for active immunization against Tetanus. The vaccine contains purified tetanus toxoid adsorbed onto aluminum salts (alum) to enhance immunogenicity and induce protective antibody responses against the toxin produced by Clostridium tetani.

Dosage Form: Injectable solution (sterile suspension for intramuscular injection) Indication: Active immunization for the prevention of tetanus Antigen: Purified tetanus toxoid adsorbed on aluminum adjuvant Administration: Intramuscular injection Type: Single-antigen tetanus vaccine (monovalent)

This vaccine is commonly used for primary immunization and booster vaccination to maintain protective immunity against tetanus.

Read more Show less

ENIMMUNE CORPORATION

  • Country/Region:
    Taiwan
  • On CPHI since:
    2026
  • Employees:
    25 - 49
Company types
Biopharmaceutical company
Distributor/Import Export
View company profile
Categories
more categories Show less
Specifications
  • Details
    Prevention of tetanus
More specifications Fewer specifications

ENIMMUNE CORPORATION

  • Country/Region:
    Taiwan
  • On CPHI since:
    2026
  • Employees:
    25 - 49
Company types
Biopharmaceutical company
Distributor/Import Export
View company profile

More Products from ENIMMUNE CORPORATION (2)

  • AdimFlu-S

    Product AdimFlu-S

    AdimFlu-S is an inactivated seasonal influenza vaccine developed by Adimmune Corporation for the prevention of influenza infection. The vaccine contains influenza virus strains recommended annually by the World Health Organization and is designed to provide protection against circulating influenza viruses....
  • EnVAX-A71

    Product EnVAX-A71

    EnVAX-A71 is an inactivated enterovirus A71 (EV-A71) vaccine developed for the prevention of EV71-associated hand, foot and mouth disease (HFMD) and herpangina in infants and young children. Manufactured using a bioreactor-based process, EnVAX-A71 demonstrated 99.21% vaccine efficacy in a multicenter Phase...